Press Release

The European Digital Pathology Vendor Landscape The European digital pathology market comprises diverse vendors ranging from large multinational healthcare IT companies to specialized startups focused on narrow market segments. No single vendor dominates the entire market—instead, vendors compete within specialized segments (enterprise platforms, image management, AI diagnostics, vendor-n

Why Applications Matter: Use Cases Determine Requirements Digital pathology is not a single application—it is a platform supporting nine distinct clinical and research use cases. Each application has different technical requirements, regulatory environments, and value propositions. Understanding the application landscape is critical because: Applications determine feature requiremen

IVDR (In Vitro Diagnostic Regulation) is European Union legislation fundamentally reshaping the digital pathology market. Unlike laboratory chemistry equipment that processes chemical reactions, digital pathology image management systems are considered "in vitro diagnostic devices"—they process diagnostic information and directly influence clinical decision-making. IVDR mandates th

Deployment model selection is a strategic infrastructure decision that affects total cost of ownership, operational complexity, scalability, compliance posture, and long-term technology flexibility. It is not a technology question that IT architects decide unilaterally—it is a business decision that should involve clinical leadership, procurement, finance, and IT stakeholders. Three facto

Traditional pathology operations are sequential and siloed. A specimen arrives at the laboratory, is assigned to a pathologist, routed through processing, prepared for microscopy, manually reviewed on glass slides, and documented in paper records or basic laboratory information systems. This linear workflow creates bottlenecks—specimens wait for pathologist availability, expertise is locked

Different therapeutic categories drive dramatically different CDMO demand patterns, manufacturing complexity, and growth rates. Understanding which therapeutic areas are driving CDMO market growth is essential for three reasons: First, if you are a CDMO provider, therapeutic area focus directly influences your service portfolio, equipment investments, and customer acquisition strategy. Oncology

Why Regulatory Compliance is the Foundation of CDMO Operations Regulatory compliance is not a secondary consideration in CDMO operations—it is the foundation upon which the entire business operates. A CDMO without FDA certification cannot serve North American pharmaceutical companies. Without EMA compliance, it cannot serve the European pharmaceutical market. Without WHO-GMP certification

The CDMO market serves eight primary customer types—from Fortune 500 pharmaceutical companies to biotech startup teams—each with fundamentally different procurement strategies, decision-making criteria, and expectations. Understanding customer segments is essential for two reasons. First, if you are a CDMO provider, your sales, marketing, and service delivery must align with your targe

Why API Type Matters for CDMO Selection The pharmaceutical API landscape has fundamentally diversified over the past two decades. Forty years ago, pharmaceutical chemistry was dominated by small-molecule chemistry—synthesized compounds created through well-understood chemical reactions. Today's pharmaceutical pipeline is dramatically different: biologics (proteins, antibodies), cell t

The pharmaceutical manufacturing landscape has evolved from a single dominant model (internal manufacturing by pharma companies) to a sophisticated ecosystem of specialized service delivery models. This diversification has been driven by three factors: rising complexity of APIs (requiring specialized expertise), cost pressures forcing manufacturing optimization, and regulatory agency preference fo